Eirini Papapetrou, MD, PhD
- PROFESSOR | Oncological Sciences
- PROFESSOR | Medicine, Hematology and Medical Oncology
Research Topics:
Cancer Genetics, Hematopoiesis, Stem Cells
Eirini Papapetrou studies blood disorders, particularly myeloid malignancies, with human pluripotent stem cells. Her lab developed the first iPSC models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. The Papapetrou lab combines expertise in induced pluripotent stem (iPS) cell generation, genome editing (CRISPR) and hematopoiesis.
Dr. Papapetrou is on Twitter at @eirinipapapetr1
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Development Regeneration and Stem Cells [DRS], Pharmacology and Therapeutics Discovery [PTD]Education
MD, University of Patras, Greece
PhD, University of Patras, Greece
Postdoctoral, Memorial Sloan-Kettering Cancer Center
-
2015
Tito Bastianello Young Investigator Award -
2014
American Society for Clinical Investigation Young Physician-Scientist Award -
2013
American Society of Hematology (ASH) Junior Faculty Scholar Award -
2013
Sidney Kimmel Foundation Scholar Award -
2013
Aplastic Anemia & MDS IF Research Grant Award -
2013
John H. Tietze Stem Cell Scientist Award -
2013
Ellison Medical Foundation New Scholar in Aging Award -
2013
Damon Runyon-Rachleff Innovation Award -
2013
UW Royalty Research Fund Award -
2011
K99/R00 Pathway to Independence Award
Research overview:
Cellular alchemy meets genome engineering
We use human pluripotent stem cells to understand the mechanisms of malignant and non-malignant blood diseases and to develop new therapies. We are harnessing somatic cell reprogramming and genetic engineering technologies to develop new models of normal and abnormal hematopoiesis. By capturing and introducing disease-associated genetic mutations and large chromosomal deletions in patient-derived induced pluripotent stem cells (iPSCs) we study their phenotypic and functional consequences, attempt to reconstruct the genetic history of leukemia progression and seek to identify new therapeutic targets through genetic screens.
Genotype-driven modeling of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis - manifested as peripheral blood cytopenia and dysplastic bone marrow (BM) - and a propensity for progression to BM failure or acute myeloid leukemia (AML) with poor prognosis. Although relatively common diseases, their pathogenesis is poorly understood.
We have recently established iPSC models of MDS that offer exciting new possibilities for the study of the molecular pathogenesis of MDS and the investigation of its genetics, clonal evolution and progression to leukemia and can provide a powerful platform for phenotype-based genetic and chemical screens to identify new therapeutic targets. We have also developed new strategies, combining AAV-mediated gene targeting with modified Cre-lox technology, as well as with the Cas9-CRISPR system, to engineer targeted chromosomal deletions in human iPSCs. These offer new opportunities to interrogate the functional consequences of large copy number variants associated with human cancer.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Papapetrou during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Regeneron Pharmaceuticals
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.